The heptadecapeptide orphanin FQ (OFQ) has been identified as the endogenous ligand for a G protein-coupled receptor (OFQ-R), which, despite its high degree of sequence similarity to opioid receptors, fails to bind opioid ligands. We developed two radioligands for the OFQ-R: a tritiated native OFQ peptide ( The molecular cloning of G protein-coupled receptors has served to vastly increase our understanding of the biology of this class of proteins over the past several years. Although the receptors for most known neurotransmitters and neuropeptides have been identified, a large number of putative receptor sequences have also been cloned for which the natural ligands are still not known; thus, these proteins have been referred to as "orphan" receptors. As a first step toward elucidation of novel neurotransmitter systems, we searched for the endogenous ligand for an opioid receptor-like orphan receptor (LC132) (1). Although this protein shares a high degree of sequence homology to the cloned -, ␦-, and -opioid receptors, no opioid ligands have been found that interact with receptor LC132 below micromolar concentrations (2). Recently, we (3) and others (4) isolated a novel neuropeptide from mammalian brain that activates the LC132 receptor with high potency. We termed this peptide OFQ and its receptor OFQ-R.
SUMMARY
The heptadecapeptide orphanin FQ (OFQ) has been identified as the endogenous ligand for a G protein-coupled receptor (OFQ-R), which, despite its high degree of sequence similarity to opioid receptors, fails to bind opioid ligands. We developed two radioligands for the OFQ-R: a tritiated native OFQ peptide ([ The molecular cloning of G protein-coupled receptors has served to vastly increase our understanding of the biology of this class of proteins over the past several years. Although the receptors for most known neurotransmitters and neuropeptides have been identified, a large number of putative receptor sequences have also been cloned for which the natural ligands are still not known; thus, these proteins have been referred to as "orphan" receptors. As a first step toward elucidation of novel neurotransmitter systems, we searched for the endogenous ligand for an opioid receptor-like orphan receptor (LC132) (1) . Although this protein shares a high degree of sequence homology to the cloned -, ␦-, and -opioid receptors, no opioid ligands have been found that interact with receptor LC132 below micromolar concentrations (2) . Recently, we (3) and others (4) isolated a novel neuropeptide from mammalian brain that activates the LC132 receptor with high potency. We termed this peptide OFQ and its receptor OFQ-R.
To further characterize this system, it is desirable to have tools that allow the pharmacological and biochemical characterization of this receptor and the determination of receptor expression in different preparations. For these purposes, we developed two peptidergic radioligands: one is a tritiated version of the native peptide ([ 3 H]OFQ), and the other is a radioiodinated derivative, based on a biologically active OFQ peptide in which Leu14 is substituted by tyrosine ( 125 ITyr14-OFQ). We have previously shown that both Tyr14-OFQ and iodo-Tyr14-OFQ are full agonists with potencies identical to the parent peptide and that 125 I-Tyr14-OFQ binds in a saturable manner to the OFQ-R expressed in CHO cells (3, 5) . However, the utility of both [ ITyr14-OFQ as radioligands depends on their ability to bind appropriately to a receptor site that exhibits properties consistent with G protein-coupled receptors, including saturability, reversibility, and modulation by environmental factors such as ions and guanine nucleotides. The results of the current study demonstrate that these radioligands bind in a reversible, saturable, and high affinity manner to OFQ-Rs heterologously expressed in HEK 293 or CHO cells. Furthermore, this interaction is characterized in terms of its modulation by monovalent and divalent cations and guanine nucleotides. Finally, we demonstrate that 125 I-Tyr14-OFQ can be used to specifically label sites in rat brain membranes that exhibit nearly identical pharmacological properties as the OFQ-R expressed in CHO cells.
Materials and Methods
Radioligands. All peptides were synthesized at Research Genetics (Huntsville, AL). Iodination and purification of Tyr14-OFQ, in which the leucine residue at position 14 of native OFQ is replaced by tyrosine, was carried out at Amersham International PLC (Buckinghamshire, UK) using the chloramine-T method (5, 6) . The product was purified by reverse-phase chromatography, yielding a specific activity of 2000 Ci/mmol (74 TBq/mmol). Eighty-two percent of the labeled product was monoiodinated on Tyr14. [ 3 H]OFQ was prepared by Amersham via catalytic hydrogenation of dehydro-Leu14-OFQ, followed by reverse-phase high performance liquid chromatography purification, yielding a specific activity of 110 Ci/mmol.
Cell culture. CHO dhfr Ϫ cells, which were stably transfected with the rat OFQ-R as previously described (3), were grown in ␣ modified Eagle's medium containing 5% fetal calf serum and 500 g/ml geneticin (G418) in a 5% CO 2 atmosphere at 37°. HEK 293 cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum in 5% CO 2 at 37°. For high level expression, the rat OFQ-R was subcloned into the eukaryotic expression vector pCEP4 (InVitrogen, San Diego, CA) and transfected into HEK 293 cells using Lipofectamine (Life Technologies, Gaithersburg, MD) according to the manufacturer's recommendations. Transfected cells were selected in the presence of 100 units/ml hygromycin (Calbiochem, San Diego, CA), and OFQ-R-expressing clones were identified by the ability of 10 nM OFQ to inhibit forskolin-stimulated cAMP accumulation as previously described (3) . All cell culture reagents were obtained from Life Technologies.
Membrane preparation. CHO and HEK 293 cells were harvested by incubation in phosphate-buffered saline plus 1 mM EDTA. Cells were washed three times with phosphate-buffered saline before resuspension in buffer A (50 mM Tris⅐HCl, pH 7.8, 5 mM MgCl 2 , 1 mM EGTA) and disruption with a tissue homogenizer (30 sec, setting 4, Pt 20, Kinematica, Kriens-Lucern, Switzerland). A total membrane fraction was obtained by centrifugation at 49,000 ϫ g at 4°. This procedure was repeated twice, and the pellet was resuspended in buffer A. Aliquots were stored at Ϫ70°, and protein concentrations were determined using the BCA Protein Assay Reagent (Pierce, Rockford, IL) following the manufacturer's recommendations. Membranes from various rat brain regions were prepared essentially as for cultured cell membranes with the exception that the following protease inhibitors were added to buffer A: 10 g/ml aprotinin, 0.1 mg/ml phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml pepstatin (all protease inhibitors were obtained from Boehringer-Mannheim Biochemica, Mannheim, Germany).
Binding assays. 125 I-Tyr14-OFQ, 50 nM unlabeled OFQ was used to define the nonspecific binding, and a 1-hr incubation time at room temperature was found to be optimal for saturation and competition assays. The assays were terminated by filtration through Whatman GF/C filters (Brandell, Gaithersburg, MD) [pretreated with 0.3% polyethylenimine (Sigma) and 0.1% bovine serum albumin (Sigma) for 1 hr] on a Brandell multichannel harvester, and the filters were washed six times with 1 ml of ice-cold 50 mM Tris⅐HCl, pH 7.5. In some cases, to avoid excessive nonspecific binding of 125 I-Tyr14-OFQ to filter materials, saturation assays were terminated by rapid cooling to 4°, followed by centrifugation at 14,000 ϫ g for 15 min at 4°. After a brief rinse with buffer A and centrifugation for 5 min at 14,000 ϫ g (4°), the membrane pellets were counted in a gamma counter. Binding parameters determined using this separation method did not differ from those determined using separation by filtration when nonspecific filter binding was not experienced. 3 H]OFQ were allowed to equilibrate for 30 min at room temperature. Then, 50 nM OFQ was added to the assay, and the incubation was continued for increasing lengths of time before termination by filtration.
Results of kinetic experiments were analyzed using the program Kinetic (Biosoft, Cambridge, UK) (7) . Saturation data were analyzed by nonlinear regression analysis using the program LIGAND (Biosoft) (8) , whereas inhibition binding data were fit to the four-parameter logistic equation using the nonlinear curve-fitting function of the program Kaleidagraph. All experiments were carried out in duplicate or triplicate and repeated at least three times. ITyr14-OFQ, the kinetics of association and dissociation were investigated using an HEK 293 cell line stably expressing the OFQ-R (293/OFQ-R). Under the conditions used for these assays, Ͻ 10% of the radioligand was bound at equilibrium, and with the assumption that these ligands interact with only one class of binding sites, the kinetics of association can be considered of pseudo-first-order. The association of both Table 1 ). The value for k a calculated in this manner did not differ significantly from the k a value calculated assuming pseudo-firstorder conditions. Thus, k a values for 125 I-Tyr14-OFQ binding to 293/OFQ-R and CHO/OFQ-R membranes were calculated using the pseudo-first-order simplification (9) ( Table 1) . Once bound, both ligands were found to dissociate in a biphasic manner, as shown for [ 3 H]OFQ in Fig. 1B , and curve fitting to two exponentials resulted in a significantly better fit than fitting to one exponential. The t 1/2 values for the two components were 7.6 and 218 min in a proportion of 55% and 45%, respectively. These values compare well with the t 1/2 values of 3.4 and 80 min obtained using 125 I-Tyr14-OFQ, although the proportion of fast and slow dissociating sites (29% and 71%, respectively) differs somewhat ( (Table 1) .
Results

Association
A distinct advantage of iodinated ligands lies in their intrinsically high specific activity. This allows the study of receptors expressed at low levels that would otherwise not be reliably detected with tritiated ligands. Because of this high specific activity, it was of interest to determine the utility of 125 I-Tyr14-OFQ in studying the OFQ-R expressed at low levels. The kinetics of association and dissociation of 125 ITyr14-OFQ were therefore investigated in CHO cells stably expressing the OFQ-R (CHO/OFQ-R) at ϳ40-fold lower levels than in the 293/OFQ-R cells. As in the 293/OFQ-R cells, association of 0.1 nM 125 I-Tyr14-OFQ was rapid and monophasic, with a t 1/2 of 158 sec (Table 1 and Fig. 1C ). I-Tyr14-OFQ bound to CHO/OFQ-R membranes was monophasic (Fig. 1D) Table 1 ), as do the proportion of high and low affinity sites that were observed. In accordance with detection of two affinity sites, Scatchard transformation of the saturation binding data was curvilinear (Fig. 2A, inset) . (Fig. 2B) . In these cells, the saturation isotherm was monophasic, as shown by a linear Scatchard transformation of the data (Fig.  2B, inset) (Fig. 3) . The addition of 5 mM NaCl had a minimal effect on [ 3 H]OFQ binding, reducing the total binding capacity byϳ10%, with no significant change in the affinity of either binding site or the proportion of the two affinity sites Table 2 ). The addition of NaCl to 120 mM resulted in the detection of only a single affinity state with a K d value of 56 Ϯ 1.1 (two experiments) pM and a 68% reduction in binding capacity (Fig. 3) . The binding of 125 ITyr14-OFQ to CHO/OFQ-R membranes was also sensitive to the presence of NaCl. In the presence of 5 mM NaCl, the K d value was increased to 165 Ϯ 2.0 (three experiments) pM, whereas the B max value was not significantly changed (90 fmol/mg of protein) (data not shown). On increasing the NaCl concentration from 5 to 100 mM, specific binding of 0.1 nM 125 I-Tyr14-OFQ was reduced by Ϸ80%, with an IC 50 value of 20 mM NaCl (Fig. 4 and Table 2 ).
The effects of Ca 2ϩ , Mn 2ϩ , and Zn 2ϩ on the binding of both radioligands was also examined. In these experiments, membranes were diluted in buffer A with a final Mg 2ϩ concentration of 0.125 mM; then, the appropriate concentration of the ion investigated was added separately. The addition of CaCl 2 , MnCl 2 , and ZnCl 2 (0.5-100 mM) caused reductions in the specific binding of both ligands, with IC 50 values of 0.6-4 mM when 0.1 nM 125 I-Tyr14-OFQ (Fig. 4 and ]OFQ by shifting the proportion of high to low affinity sites from 47% high/53% low to 15% high/85% low (Fig. 5A ). There was no significant change in the total binding capacity or in the K d value of either affinity site. In CHO/OFQ-R membranes, the addition of 200 M Gpp(NH)p reduced the affinity of 125 ITyr14-OFQ binding by 43%, from 57 to 134 pM, with little change in the B max value (94-83 fmol/mg of protein) (Fig.  5B) . Under these conditions, nonlinear curve fitting revealed the presence of only a single class of binding sites, as was observed in the absence of Gpp(NH)p.
The specificity of the guanine nucleotide effect was investigated by comparing the ability of several nucleotides to reduce the binding of [ (Fig. 6) . The nucleotides GMP, ATP, and AMP had no effect on [ 3 H]OFQ binding. 125 I-Tyr14-OFQ binding in rat brain and peripheral tissue membranes. Because the mRNA for OFQ-R has been shown to be widely distributed in the brain (1, 2), we attempted to determine whether 125 I-Tyr14-OFQ could be used to detect OFQ-R binding activity in membranes prepared from different brain regions. As shown in Fig. 7 , specific, saturable 125 I-Tyr14-OFQ binding could be detected in membranes prepared from cerebral cortex. Analysis of the saturation isotherm yielded a K d value of 65.9 Ϯ 6.8 pM (three experiments), which is in good agreement with the value observed in CHO/OFQ-R cells. Next, we evaluated the level of OFQ-R expressed in different rat brain regions. Table 3 indicates that highest expression level of OFQ-R was detected in the hypothalamus, followed by the hippocampus, thalamus, and cortex (507, 489, 249, and 226 fmol/mg of protein, respectively). Other brain regions, including the striatum, cerebellum, and midbrain, contained modest-to-low levels of OFQ-R with no detectable binding in the pituitary. Again, analysis by nonlinear curve fitting revealed only a single class of binding sites in all regions examined, with Hill 125 I-Tyr14-OFQ for 1 hr at room temperature before termination of the assay by filtration as described in Materials and Methods. Nonspecific binding was estimated using 50 nM cold OFQ. Specific 125 I-Tyr14-OFQ binding in the absence of added ions (other than MgCl 2 ) was ϳ12,600 dpm, whereas nonspecific binding was ϳ2200 dpm. Values represent the percentage of specific binding in the absence of added ions and are mean Ϯ standard error of three independent experiments performed in triplicate. (Table 3) . No specific binding of 125 I-Tyr14-OFQ was detected in peripheral tissues, including the spleen, thymus, kidney, intestine, heart, lung, and skeletal muscle.
To verify that 125 I-Tyr14-OFQ binding in cortical membranes represents specific interaction with the native OFQ-R, we examined the ability of several alanine-substituted OFQ analogs to inhibit 125 I-Tyr14-OFQ binding to cortex membranes. We have previously shown that alanine substitution at positions 1, 4, and 8 in the OFQ molecule (Ala1-OFQ, Ala4-OFQ, Ala8-OFQ, respectively) negatively affects biological activity as measured by the inability of these analogs to inhibit forskolin-stimulated cAMP accumulation in CHO/OFQ-R cells and by their reduced binding affinity compared with native OFQ (5). These analogs were thus used as pharmacological agents to further characterize the site of 125 I-Tyr14-OFQ binding in cortical membranes. Displacement of 125 I-Tyr14-OFQ binding in cortex membranes by these substituted OFQ analogs was in agreement with K i values determined in membranes from CHO/OFQ-R cells (Table 4) , with the rank order of potency being OFQ Ͼ Ala1-OFQ ϭ Ala8-OFQ Ͼ Ala4-OFQ. These results indicate that 125 I-Tyr14-OFQ binds to a site in cortex membranes that is phamacologically indistinguishable from the cloned OFQ-R expressed in CHO cells.
Discussion
In the present study, we characterized the interaction of two peptidergic radioligands with the receptor for a novel neuropeptide, OFQ. The results of this study revealed that both the tritiated, native OFQ ([ 3 H]OFQ) and the radioiodinated, Tyr14-substituted analog ( 125 I-Tyr14-OFQ) interacted with the OFQ-R in a virtually identical manner. These radioligands met the criteria of saturability, reversibility, and low nonspecific binding that are necessary for useful radioligands. In addition, the binding of these radioligands was found to be modulated by environmental factors known to modulate agonist binding in other receptor systems.
In our first studies of I-Tyr14-OFQ from OFQ-R expressed in CHO cells occurred in a monophasic manner, with a relatively long t 1/2 value of 3.2 hr. Comparison of the slow components of dissociation from 293/OFQ-R with dissociation of 125 I-Tyr14-OFQ from CHO/OFQ-R suggested that both ligands recognize the same high affinity state of the receptor in both cell lines but that the low affinity state is not present in the CHO cell line. Such a result may be due to the difference in expression level of OFQ-R between the two cell lines and suggests that in the CHO cell line, the OFQ-R may be very tightly coupled to G proteins.
In accord with the clear presence of two affinity states for agonist binding to the OFQ-R in HEK 293 cells, as revealed by kinetic experiments, two affinity states were likewise observed in saturation binding experiments. The affinities for these sites, calculated by nonlinear curve fitting of the saturation isotherm, agreed well with the kinetically determined values for both the high and low affinity sites for both radioligands, indicating that under the conditions used for saturation binding, both radiolabeled OFQ ligands bind to two affinity states of the OFQ-R according to the law of mass action.
The presence of two affinity states for agonist binding is common in G protein-coupled receptors and is often taken to indicate a functional interaction with signal-transducing G proteins. That this is the case for the OFQ-R is demonstrated by the effect of the nonhydrolyzable guanine nucleotide analog Gpp(NH)p on radiolabeled OFQ binding. In the 293/ OFQ-R cells, the addition of Gpp(NH)p resulted in a shift in the proportion of high to low affinity states of the OFQ-R. In the absence of guanine nucleotides, ϳ50% of the OFQ-R is in the high affinity state, presumably coupled to G proteins. In the presence of Gpp(NH)p, the percentage of high affinity sites is reduced to 15%, whereas the total number of binding sites remains virtually the same. This indicates that the bulk of the receptor has been shifted to the low affinity state, which is considered to be uncoupled from G proteins. In CHO/OFQ-R cells, 100% of the receptor appears to be in the high affinity, G protein-coupled state in the absence of guanine nucleotide, as demonstrated by monophasic kinetic and saturation binding analysis. The addition of Gpp(NH)p to membranes from these cells resulted in virtually complete conversion of receptor sites from high affinity to low affinity. That this effect is mediated by G proteins is indicated by the finding that only guanine, not adenine, nucleotides are able to modulate OFQ radioligand binding.
For G protein-coupled receptors, ligand binding, and agonist ligand binding in particular, is often also modulated by the presence of ions such as Na ϩ and Mg 2ϩ . In general, Na ϩ seems to reduce the affinity of agonist binding, whereas antagonist binding is less affected (10 On the other hand, specific binding of radioligands to the OFQ-R was decreased by increasing concentrations of Na ϩ with an IC 50 value of 20 mM. Although the site for Na ϩ modulation of ligand binding has been proposed to be a conserved aspartic acid residue in transmembrane region 2 for a wide variety of G protein-coupled receptors, including the rat OFQ-R, the precise molecular mechanism remains to be elucidated (22) .
Other divalent cations were also found to modulate the binding of both OFQ radioligands. have been reported to improve agonist and antagonist binding to opiate receptors (9) . It is also interesting that neither of these cations is able to substitute for the Mg 2ϩ required for high affinity binding of the OFQ radioligands. At the present time, we are unable to account for these discrepancies because our knowledge on the mechanism of action of the cations is limited. In contrast, the inhibition of OFQ binding by Zn 2ϩ agrees well with a previous finding regarding the effect of this cation on enkephalin binding to opiate receptors (23) .
Having shown that 125 I-Tyr14-OFQ is a high specific activity agonist and a valid ligand for heterologously expressed OFQ-Rs, we used it to quantify OFQ binding sites in different tissues. The highest levels of 125 I-Tyr14-OFQ binding were found in the hypothalamus and hippocampus, followed by the thalamus and cerebral cortex. Lower levels of binding were observed in the striatum, midbrain, and cerebellum. In all regions where specific binding was observed, 125 I-Tyr14-OFQ bound to a single class of saturable, high affinity sites, with K d values that were not significantly different from the those for OFQ-R expressed in CHO cells. Interestingly, saturation binding analysis revealed that in general, 125 I-Tyr14-OFQ binding correlated very well with the abundance and distribution of mRNA for the OFQ-R previously reported by several groups (1, 2, 24) .
We chose to further characterize the properties of 125 ITyr14-OFQ binding in brain by examining the ability of several OFQ peptide analogs to displace its binding from cortical membranes. For all peptides tested, both the affinity and rank order of inhibition of 125 I-Tyr14-OFQ binding were similar to those seen in membranes from CHO cell membranes. These results indicate that in brain membranes, 125 I-Tyr14-OFQ labels a receptor site with pharmacological properties identical to those exhibited by the OFQ-R heterologously expressed in CHO cell membranes.
The results presented here demonstrate that the radioligands 125 I-Tyr14-OFQ and [ 3 H]OFQ are high specific activity agonists that can be used for analyzing the properties and functions of the OFQ-R in transfected cells and native tissue preparations. Both ligands behave in a nearly identical manner; however, each ligand offers distinct advantages.
125
ITyr14-OFQ, with its very high specific activity, will be useful for studies of the OFQ-R in native tissues in which expression levels may be relatively low. [ 3 H]OFQ, on the other
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hand, has the advantage of being identical to the native peptide and thus is likely to be a preferable ligand for detailed studies of the interactions between the OFQ peptide and its receptor, as well as for pharmacological characterizations of the OFQ-R. Given their respective advantages, the use of these radioligands will promote an enhanced understanding of the biology of this novel neuropeptide system at the molecular level.
